Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-027348
Filing Date
2025-02-26
Accepted
2025-02-26 08:44:46
Documents
107
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K tsha-20241231.htm   iXBRL 10-K 3368005
2 EX-19.1 tsha-ex19_1.htm EX-19.1 70268
3 EX-23.1 tsha-ex23_1.htm EX-23.1 3062
4 EX-31.1 tsha-ex31_1.htm EX-31.1 17099
5 EX-31.2 tsha-ex31_2.htm EX-31.2 17114
6 EX-32.1 tsha-ex32_1.htm EX-32.1 10215
7 EX-32.2 tsha-ex32_2.htm EX-32.2 9935
8 GRAPHIC img39598004_0.jpg GRAPHIC 139168
9 GRAPHIC img39598004_1.jpg GRAPHIC 373608
10 GRAPHIC img39598004_2.jpg GRAPHIC 411975
11 GRAPHIC img39598004_3.jpg GRAPHIC 449774
12 GRAPHIC img39598004_4.jpg GRAPHIC 406829
13 GRAPHIC img39598004_5.jpg GRAPHIC 124841
14 GRAPHIC img39598004_6.jpg GRAPHIC 365222
15 GRAPHIC img39598004_7.jpg GRAPHIC 436629
16 GRAPHIC img39598004_8.jpg GRAPHIC 428850
  Complete submission text file 0000950170-25-027348.txt   22251205

Data Files

Seq Description Document Type Size
17 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tsha-20241231.xsd EX-101.SCH 1947771
110 EXTRACTED XBRL INSTANCE DOCUMENT tsha-20241231_htm.xml XML 2570218
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39536 | Film No.: 25666309
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)